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Abstract
Primase and DnaB helicase play central roles during DNA replication initiation and elongation. Both enzymes are drug
targets because they are essential, persistent among bacterial genomes, and have different sequences than their eukaryotic equivalents. Myricetin is a ubiquitous natural product in plants that is known to inhibit a variety of DNA polymerases,
RNA polymerases, reverse transcriptases, and telomerases in addition being able to inhibit kinases and helicases. We have
shown that myricetin inhibits Escherichia coli DnaB helicase according to a mechanism dominated by noncompetitive behavior with a Ki of 10.0 ± 0.5 μM. At physiological ATP concentration, myricetin inhibits E. coli DnaB helicase with an inhibitory concentration at 50% maximal (IC50) of 11.3 ± 1.6 μM. In contrast, myricetin inhibited E. coli primase at least 60fold weaker than DnaB helicase and far weaker than any other polymerase.
Keywords: Myricetin, DNA replication, DnaB helicase, Primase, Escherichia coli
Abbreviations: ssDNA = single-stranded DNA

1. Introduction
Helicase and primase are required during DNA replication because DNA is an antiparallel duplex and because no
replicative DNA polymerase is able to initiate polymers de
novo. Primase is a specialized DNA-dependent RNA polymerase that generates short oligoribonucleotide polymers de
novo that can be elongated by DNA polymerase.1, 2 During
DNA replication, primase initiates the leading strand synthesis at least once and the lagging strand synthesis many times.
Even though all autonomous life forms store their genetic information in duplex DNA and use a primase to initiate leading
and lagging strand DNA synthesis, the primases from archaea
and eukaryotes are structurally unrelated to the primases from
prokaryotes.3, 4 In Escherichia coli, conditionally lethal mutations in the primase gene yield lethal phenotypes under the
non-permissive conditions, demonstrating the essentiality of
the enzyme.5, 6 The indispensable function of primase and the
structural divergence of the eukaryotic and prokaryotic primases have led to the identification of the enzyme as a target
for novel antibiotic development.7, 8

The DnaG protein from E. coli is the model eubacterial
primase because its structure and function have been extensively characterized. It has been demonstrated that E. coli
DnaG primase is slow, binds ssDNA as a dimer, and that interaction with DnaB helicase stimulates its catalytic activity over 15-fold.9–12 E. coli DnaG primase specifically initiates RNA primer synthesis complementary to the trinucleotide
5′-d(CTG)-3′ in vitro, and E. coli Okazaki fragment initiation maps to a d(CTG) on the chromosomal template strand
in vivo.13, 14
DnaB helicase from E. coli is the model eubacterial helicase that unwinds duplex DNA at the replication fork so that
the two strands can be replicated by the combination of primase and DNA polymerase.15 In E. coli, conditionally lethal
mutations in the dnaB gene yielded lethal phenotypes under
the non-permissive conditions, demonstrating the essentiality
of the gene product for replication elongation and initiation.16–
20 During the initiation phase of replication, E. coli DnaB helicase interacts with DnaA origin-binding protein, DnaC helicase loading protein, and primase.21, 22 During the elongation
phase, dimeric DNA polymerase III is tethered to the helicase
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Figure 1. The structures of (a) myricetin and (b) quercetin differ with regard to the hydroxyls on carbons 3 and 5′. Tests with a variety of flavonoids revealed that
the 3′ and 5′ hydroxyls of myricetin were very important for its ability to inhibit RSF1010 RepA helicase better than the other flavonoids.57

via its tau subunit and primase repeatedly and transiently interacts with the helicase to initiate lagging strand synthesis.23,
24 During the termination phase, the replication machinery
is prevented from over-replicating the genome by the inhibitory interaction between the Tus protein and DnaB helicase.25
As the central hub of the replication machinery and given the
structural divergence of the eukaryotic and prokaryotic fork
helicases, DnaB is considered to be a novel target for antibiotic development.
High-throughput assays have been developed for helicase
activity, primase activity, and helicase-stimulated primase activity to identify novel inhibitors of these two enzymes.7, 26–
28 Primase activity assays have been used to identify several
natural product inhibitors, such as a bicyclic macrolide, two
phenolic saccharides, and a group of synthetic compounds
identified from a series of virtual and real screens.8, 29, 30 The
phenolic saccharides are not good leads because they inhibit
primase activity through their ability to bind to ssDNA and
thereby occlude primase. Helicase activity assays have identified inhibitors from among the known families of flavonols
and triaminotriazines.31, 32 These families of compounds inhibit many helicases and/or kinases.31–33
Flavonoids provide flavor and color to all parts of
plants. Over 5,000 different flavonoids, including myricetin
and quercetin (Figure 1), have been described and some of
them have been tested for biological activity.34 Many flavonoids have anti-carcinogenic and antibacterial activities but
the sites of action are known for only a few.35 One of the
exceptions is that quercetin’s antimicrobial activity can be
attributed in part to its inhibition of gyrase. Myricetin has
been shown to have antimicrobial activity but it has not been
possible to attribute its effect to any one target. Determining its target has been difficult because flavonoids tend to
aggregate, adhere to the container surface, and immobilize
the enzyme being assayed so that it is inactivated by a nondrug-like mechanism.36, 37 Nevertheless, careful analysis has
shown that myricetin and quercetin inhibit a variety of DNA
polymerases, RNA polymerases, reverse transcriptases, and
telomerases.38–41
In the present study, it was discovered that DnaB helicase activity was 60 times more sensitive to myricetin than
was primase activity. In fact, primase was the least myricetin-sensitive of all polymerases tested so far. The myricetin
inhibition kinetics of the DnaB ATPase activity were consis-

tent with simple noncompetitive inhibition with physiological
amounts of the substrate ATP.
2. Results
The purpose of this study was to determine the extent to
which myricetin was capable of inhibiting E. coli DnaB helicase, primase, and DnaB-stimulated primase activity. The results showed that DnaB helicase was much more sensitive to
myricetin than was primase.
2.1. Myricetin inhibition of DnaB ATPase activity
After some preliminary experiments to establish the best
range of concentrations, the inhibition of DnaB ATPase activity was analyzed as a function of ATP and myricetin. In the
absence of myricetin (Figure 2a and b), the ATP concentration dependence exhibited hyperbolic saturation kinetics with
a KM of 31 μM ATP and Vmax = 2870 nM/s (Table 1). These
were similar to reported values.42, 43 Hyperbolic kinetics indicated that all of the ATP active sites were equal and noninteracting even though the enzyme has six identical subunits per functional complex. As the myricetin was increased
to 12 μM, the apparent Vmax decreased 2.7-fold whereas the
apparent KM decreased 11-fold. The decrease in the apparent KM was not consistent with competition between ATP and
myricetin for the active site. Simple competitive inhibition
would have increased the KM according to the relationship of
K′M = KM (1 + [I]/Ki), where K′M is the apparent KM and Ki
is the median inhibition concentration. When myricetin was
increased to 30 μM, the apparent KM and apparent Vmax decreased by about the same amount indicating that the kinetic
affinity for ATP was no longer being so dramatically affected.
Higher myricetin concentration led to a continued decrease
in apparent Vmax but an increase in the apparent KM, which
was finally consistent with some small degree of competitive
inhibition.
The decrease in apparent Vmax suggested that it may be
due to noncompetitive inhibition, in which the inhibitor is
able to bind to both the free enzyme and the enzyme–substrate
complex to create a “dead end” complex that is inactive. Simple noncompetitive inhibition decreases the Vmax according to
the relationship of V′max = V max/(1 + [I]/Ki), where V′max is the
apparent Vmax and Ki is the median inhibition concentration.
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Figure 2. The effect of ATP and myricetin on E. coli DnaB ATPase. In panels a and b, the myricetin concentrations were 0 μM (•), 6 (○), 12 (■), 30 (□), and 60
(▲). In panel c, apparent kinetic constants from the data were plotted versus myricetin concentration. In panel d, the ATPase activity was replotted versus myricetin concentration such that the ATP concentrations were 1 μM (•), 3 μM (■), 10 μM (▲), 150 μM (○), and 1 mM ATP (□).

Table 1. Apparent Michaelis–Menten constants for E. coli DnaB helicase in the presence of myricetin
Myricetin (μM)

V ′max(μM/s)

K′M(μM)

R2

0
6
12
30
60

2.87 ± 0.09
1.64 ± 0.08
1.06 ± 0.07
0.61 ± 0.04
0.35 ± 0.05

31 ± 3
17 ± 3
2.9 ± 0.9
2.3 ± 0.8
4.5 ± 3.1

0.998
0.989
0.958
0.952
0.801

The mathematical inversion of this equation (1/V′max = 1/
V max/(1 + [I]/Ki) indicates that a plot of 1/V′max versus [I]
will be linear if it conforms to noncompetitive inhibition
and that the slope and y-intercept can be used to determine
the inhibition constant. When the data were so plotted, they
yielded a linear relationship (Figure 2c circles) and a Ki of
10.0 ± 0.5 μM. Therefore, the decrease in enzyme activity as
a function of myricetin at saturating ATP was due to noncompetitive inhibition.
To determine the inhibitor concentration that causes
50% inhibition, IC50, the ATPase activity was replotted versus myricetin concentration (Figure 2d). At the highest ATP
concentrations, 150 μM (solid line) and 1 mM (dashed
line), the data conformed to the inhibition equation: %
activity = Ymax − Ymax [I]/(IC50 + [I]). Fitting the 150 μM ATP
data revealed that the Ymax was 2340 ± 50 nM/s and IC50 was

10.2 ± 0.6 μM myricetin with an R2 of 0.997. At 1 mM ATP,
the Ymax was 2510 ± 110 nM/s and IC50 was 11.3 ± 1.6 μM
myricetin with an R2 of 0.986. These values were statistically
the same as the Ki, showing that the dominant inhibition mechanism at high and saturating ATP was noncompetitive. An examination of the myricetin effect (Figure 2d) further showed
that myricetin stimulated ATPase when its concentration was
less than 12 μM and the ATP concentration was less than
10 μM. At these low non-physiological ATP concentrations
(Figure 2d), the KM effects (Figure 2c) indicate that myricetin binding to non-active sites was able to enhance ATPase activity by increasing the enzyme’s kinetic affinity for ATP more
than its Vmax decreases.
2.2. Myricetin inhibition of primase alone
The ability of myricetin to inhibit primase activity in the
absence of DnaB was tested because it is an inhibitor of a variety of DNA polymerases, RNA polymerases, and reverse
transcriptases.38–41 This was also an important control for the
more physiologically relevant reaction of DnaB-stimulated
primer synthesis. When myricetin was added to the reaction
containing primase and its substrates, it barely inhibited in a
concentration-dependent manner (Figure 3). It was not possible to test higher myricetin concentrations due to myricetin’s
low solubility. Even though the error in each measurement is
about 5%, the same scale as the effect, fitting of the data to the
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Figure 3. The effect of myricetin on E. coli primase activity in the presence
(•) and absence (○) of E. coli DnaB helicase. Each data set was normalized
to the number of primers synthesized in the absence of myricetin. In the absence of helicase, primase activity was weakly inhibited and poorly fit but the
constants were Ymax = 99 ± 2%, IC50 = 700 ± 300 μM myricetin, and an R2 of
0.634. DnaB-stimulated primer synthesis could not be fit to a hyperbolic relationship so a line was drawn through the data to show the trend.

inhibition equation revealed that the IC50 was 700 ± 300 μM
myricetin. The consequence was that myricetin inhibited primase activity 60 times weaker than it inhibited DnaB ATPase
activity and much weaker than the low micromolar IC50’s for
DNA polymerases, RNA polymerases, reverse transcriptases,
and telomerases. 38–41 It may be relevant that the structure of
bacterial primase differs from those palm-type nucleic acid
polymerases in that it has a ‘cashew-shaped’ active site shared
by no other polymerase family.44, 45
2.3. Myricetin inhibition of DnaB-stimulated primer
synthesis
Primase and DnaB stimulate each other’s activities.46 Of
these cross-reactivities, the DnaB stimulation of primer synthesis activity is the most relevant to DNA replication because
DNA polymerase cannot synthesize DNA without the resulting primer. Therefore, primer synthesis by primase was measured with and without helicase as a function of myricetin
concentration. Unfortunately, the controls without myricetin
but with DMSO showed that 0.5–4% DMSO, which would be
added with 10–40 μM myricetin as its solvent, completely inhibited the helicase stimulation when it was present at its most
stimulatory ratio relative to the primase. 12, 13, 46 This reduced
level of primase activity was the same as primase alone and
may reflect a slight stimulation effect by the myricetin (Figure
3). Therefore, DMSO may not cause primase and helicase to
dissociate from each other, but rather the presence of helicase
may alter the ability of primase to be inhibited by myricetin.
3. Discussion
Myricetin is one of the six major flavonoids, plant pigments found in many foods and beverages, that are nutrition-
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ally interesting primarily for their antioxidant activities.47 We
show here that myricetin inhibits homohexameric E. coli DnaB
with a Ki and IC50 of about 10 μM. The results also showed
that myricetin would be an effective inhibitor at the log-phasegrowth-phase ATP concentration of 3 mM.48 The inhibitory
mechanism was noncompetitive, indicating that myricetin does
not bind to the active site. Even though the mechanism for
ATP hydrolysis by hexameric helicases is complex, the current
model for DnaB is that ATP can bind and be hydrolyzed in the
active site of every other subunit.49 Binding of ATP to the remaining three subunits is weaker and negatively cooperative.50
For these reasons, it is interesting to speculate that myricetin is
binding to the unfilled active sites to shut down the hydrolytic
activity of the ATP-bound active sites.
The unwinding mechanism of the T7 gene 4 protein, a
DnaB homolog, has been proposed to pass ssDNA from one
subunit to another within the toroid as each adjacent subunit
binds ATP, hydrolyzes it, and then releases ADP and phosphate.51 When myricetin concentration is low, it must bind at
or near the ATP pocket of one subunit such that it stimulates
ATP synthesis in adjacent subunits. When myricetin concentration is moderate or high, it must bind to more than one subunit to lock the homohexamer into an inactive complex.
Other studies have shown that myricetin inhibited
RSF1010 RepA, a distant hexameric helicase homolog, with a
Ki = 23 μM and IC50 = 50 μM.31 This is substantially weaker
than the inhibition of DnaB helicase described here. The
RepA myricetin inhibition kinetics also differed from those
with DnaB in that they were competitive. Nevertheless, of the
several flavonoids this group tested, myricetin was the most
effective at inhibiting cellular growth. The minimal inhibitory concentration for E. coli was 0.50 mg/mL and for Bacillus subtilis was 0.25 mg/mL.31
RSF1010 RepA differs from both bacterial DnaB and
T7 gene 4 protein in that it lacks a distinct N-terminal domain.52, 53 Specifically, DnaB is composed of three domains:
the N-terminal domain (NTD or DnaBα), the ATPase shoulder
(DnaBβ), and the C-terminal hexamerization domain (DnaBγ).
Bacterial primase binds to the linker that connects the DnaB
NTD with its ATPase domain.54 Even though RepA interacts with RepC initiator protein and RepB′ primase, neither
of those two enzymes is related by sequence to either E. coli
DnaA or DnaG primase. Our results indicate that RSF1010
RepA is not a good model for DnaB perhaps because it lacks
an N-terminal interaction domain.
There is only one crystal structure of inhibitory myricetin bound to one of its targets phosphatidylinositol-3-kinase
(PIK3) (1E90.pdb).55 Myricetin and 13 other flavonoids are
low micromolar competitive inhibitors of PIK3, which is involved in signal transduction.56 Given that they inhibited with
similar affinities, it was remarkable to find that every one of
the five co-crystallized flavonoids adopted a different orientation within the PIK3 ATP site. For instance, myricetin
bound at a different angle than the structurally similar quercetin (1E8W.pdb). Nevertheless, since the ATPase sites of RepA
and DnaB are smaller than the ATP binding site of PIK3, it
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should be possible to design compounds that fit more snugly
into their active sites.
New and emerging pathogenic bacteria and the rise in
multi-drug-resistant bacterial strains are driving the need to
discover novel antibiotics. Only a few DNA replication enzymes are targets for current antibiotics. Bacterial primase and
DnaB helicase are novel targets that are beginning to generate
lead compounds from among natural products. In future studies, we will use structural models of the DnaB helicase active
site to help engineer myricetin’s structure to improve its selectivity and strength.
4. Materials and methods
4.1. Reagents
The E. coli DnaB helicase and primase were expressed
and purified as described.58, 12 Ribonucleoside triphosphates
(NTPs) were from Promega (Madison, WI). Myricetin, magnesium acetate, potassium glutamate, Hepes, and DTT were
from Sigma (St. Louis, MO). Myricetin was dissolved in ethanol and its stock concentration determined using an extinction coefficient at 378 nm of 20,400 M−1 cm−1.59 It was then
diluted into DMSO for use in the experiments.
4.2. Coupled ATPase assay

7207

nucleotide underlined in the template sequence. After incubation at 30 °C for 1 h, the samples were desalted through a Microspin G-25 column (Amersham, Piscataway, NJ) and then
separated by thermally denaturing HPLC on a WAVE HPLC
Nucleic Acid Fragment Analysis System with a DNASep
HPLC column from Transgenomic (Omaha, NE).
4.4. Data-fitting
The data were fit to the indicated equations using Prism 4
for Macintosh (GraphPad Software, San Diego, CA).
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